Celebrate Las Vegas PRIDE in October with Colorful Events, Parades, Pool Parties and More
Las Vegas celebrates the LGBTQ+ community year-round, along with the standout celebration…
Proxgy Founder and CEO Pulkit Ahuja Receives Dual Honors during MSME Ceremony at Vigyan Bhawan
Recognitions include 'Founder of the Year' and 'MSME Make in India Initiative…
LBB Specialties Expands Partnership with Givaudan Active Beauty in the Midwest & East United States
NORWALK, Conn., Oct. 7, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a North…
CoinW to Showcase “Crypto Marathon Spirit” at TOKEN2049 Singapore, Marking 8 Years of Innovation
HONG KONG, Sept. 24, 2025 /PRNewswire/ -- CoinW, a leading global cryptocurrency…
Las Vegas Kicks Off The Fabulous 5Day Sale Today
First Ever City-Wide Sale Available Sept. 22-26; Offers Include up to 50%…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
Grvt Raises $19M to Pioneer Privacy-First Onchain Finance and Unlock Trillion-Dollar Markets
PANAMA CITY, Sept. 19, 2025 /PRNewswire/ -- Grvt, the preeminent DEX (decentralized…
NYSE Content Advisory: Annual International Day Slate Announced
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The New York Stock Exchange…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
![U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease](https://i3.wp.com/mms.businesswire.com/media/20250905840795/en/1247790/22/Takeda_Red_Logo_2021.jpg?w=420&resize=420,280&ssl=1 "U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease"){kind=logo}
U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce…
